Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010
- PMID: 26459813
- PMCID: PMC4677421
- DOI: 10.1093/neuonc/nov249
Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010
Abstract
Background: Years of potential life lost (YPLL) complement incidence and survival rates by measuring how much a patient's life is likely to be shortened by his or her cancer. In this study, we examine the impact of death due to brain and other central nervous system (CNS) tumors compared to other common cancers in adults by investigating the YPLL of adults in the United States.
Methods: Mortality and life table data were obtained from the Centers for Disease Control and Prevention's National Center for Health Statistics Vital Statistics Data for 2010. The study population included individuals aged 20 years or older at death who died from one of the selected cancers. YPLL was calculated by taking an individual's age at death and finding the corresponding expected remaining years of life using life table data.
Results: The cancers with the greatest mean YPLL were other malignant CNS tumors (20.65), malignant brain tumors (19.93), and pancreatic cancer (15.13) for males and malignant brain tumors (20.31), breast cancer (18.78), and other malignant CNS tumors (18.36) for females. For both sexes, non-Hispanic whites had the lowest YPLL, followed by non-Hispanic blacks, and Hispanics.
Conclusion: Malignant brain and other CNS tumors have the greatest mean YPLL, thereby reflecting their short survival time post diagnosis. These findings will hopefully motivate more research into mitigating the impact of these debilitating tumors.
Keywords: CBTRUS; NCHS; central nervous system tumors; years of potential life lost.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Comment in
-
Quantifying the burden of primary central nervous system malignancy.Neuro Oncol. 2016 Jan;18(1):5-6. doi: 10.1093/neuonc/nov287. Epub 2015 Nov 20. Neuro Oncol. 2016. PMID: 26590383 Free PMC article. No abstract available.
Similar articles
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150. Neuro Oncol. 2019. PMID: 31675094 Free PMC article.
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200. Neuro Oncol. 2020. PMID: 33123732 Free PMC article.
-
Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009.Cancer Med. 2015 Apr;4(4):608-19. doi: 10.1002/cam4.410. Epub 2015 Jan 27. Cancer Med. 2015. PMID: 25627000 Free PMC article.
-
Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.Urology. 2010 Sep;76(3):528-35. doi: 10.1016/j.urology.2010.04.030. Epub 2010 Jun 22. Urology. 2010. PMID: 20573389 Review.
-
Epidemiologic impact of children with brain tumors.Childs Nerv Syst. 1999 Nov;15(11-12):758-63. doi: 10.1007/s003810050467. Childs Nerv Syst. 1999. PMID: 10603019 Review.
Cited by
-
Health Related Quality of Life in Adult Low and High-Grade Glioma Patients Using the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL Assessments.Front Neurol. 2019 Mar 15;10:212. doi: 10.3389/fneur.2019.00212. eCollection 2019. Front Neurol. 2019. PMID: 30930834 Free PMC article.
-
shRNA-mediated PPARα knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth.J Pathol. 2019 Apr;247(4):422-434. doi: 10.1002/path.5201. Epub 2018 Dec 27. J Pathol. 2019. PMID: 30565681 Free PMC article.
-
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.Neuromolecular Med. 2022 Jun;24(2):113-124. doi: 10.1007/s12017-021-08667-x. Epub 2021 Jun 1. Neuromolecular Med. 2022. PMID: 34075570
-
MEOX2 promotes glioma growth and temozolomide chemoresistance.J Pharm Anal. 2024 Sep;14(9):100912. doi: 10.1016/j.jpha.2023.12.002. Epub 2023 Dec 10. J Pharm Anal. 2024. PMID: 39291243 Free PMC article.
-
Disparities in Neuro-Oncology.Curr Neurol Neurosci Rep. 2023 Dec;23(12):815-825. doi: 10.1007/s11910-023-01314-x. Epub 2023 Oct 27. Curr Neurol Neurosci Rep. 2023. PMID: 37889427 Review.
References
-
- Siegel R, Miller K, Jemal A. Cancer statistics, 2015. Ca Cancer J Clin. 2015;65(1):5–29. - PubMed
-
- Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep. 2013;62(6):1–96. - PubMed
-
- Gardner JW, Sanborn JS. Years of potential life lost (YPLL)—what does it measure? Epidemiology. 1990;1(4):322–329. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical